Free Trial
NASDAQ:PMVP

PMV Pharmaceuticals Q4 2025 Earnings Report

PMV Pharmaceuticals logo
$1.45 +0.08 (+5.84%)
Closing price 04:00 PM Eastern
Extended Trading
$1.45 0.00 (0.00%)
As of 06:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

PMV Pharmaceuticals EPS Results

Actual EPS
-$0.34
Consensus EPS
-$0.40
Beat/Miss
Beat by +$0.06
One Year Ago EPS
N/A

PMV Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

PMV Pharmaceuticals Announcement Details

Quarter
Q4 2025
Time
Before Market Opens
Conference Call Date
Friday, March 6, 2026
Conference Call Time
7:00AM ET

Upcoming Earnings

PMV Pharmaceuticals' Q1 2026 earnings is estimated for Friday, May 8, 2026, based on past reporting schedules

PMV Pharmaceuticals Earnings Headlines

Elon’s Biggest Launch Ever: 15x Bigger Than SpaceX
The Man Who Called Nvidia Before It Soared 1,000% Issues New Elon Musk BUY Alert Luke Lango was ranked America's #1 stock picker in 2020. He was mentored by two hedge fund billionaires from the Soros network and trained at Caltech. His readers have had the chance to see gains as high as AMD +8,500%... Nvidia +5,000%... Tesla +3,500%... Palantir +1,000%... and Apple +890%.tc pixel
PMV Pharmaceuticals Announces Board Chair Transition
See More PMV Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like PMV Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on PMV Pharmaceuticals and other key companies, straight to your email.

About PMV Pharmaceuticals

PMV Pharmaceuticals (NASDAQ:PMVP), a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey.

View PMV Pharmaceuticals Profile